Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

NPS Pharmaceuticals (NPSP)

Add to Watchlists
Create an Alert
25.88 -0.70  -2.63% NASDAQ Apr 23, 4:59PM BATS Real time Currency in USD
View Full Chart
NPSP Price Chart
View All Events

NPSP Events

Date Type Description
May 07 Misc AGM Event for NPS Pharmaceuticals Inc.
View All Performance Charts

NPSP Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). NPS Pharmaceuticals is up 100.5% over the last year vs S&P 500 Total Return up 22.59%, Alexion Pharmaceuticals up 68.04%, and Jazz Pharmaceuticals up 160.8%.

Get Quote for

PDF Report for NPSP

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download NPSP Pro Report PDF

Portfolio Strategies Featuring NPSP

Did NPS Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

NPSP Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: New Jersey
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Biological Product (except Diagnostic) Manufacturing
  • NAICS Code: 325414
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

NPS Pharmaceuticals, Inc. engages in the discovering, developing and commercializing small molecule drugs and recombinant proteins. Its existing product candidates are primarily for the treatment of bone and mineral, gastrointestinal and central nervous system disorders. The company is currently advancing two late-stage programs. Teduglutide, a proprietary analog of glucagon and preclinical development for additional intestinal failure related conditions. NPSP558 is a clinical development as a hormone therapy for hypoparathyroidism. Its product portfolio consists of a United States Food and Drug Administration approved product, as well as product candidates in various stages of clinical development and preclinical development. NPS Pharmaceuticals, Inc. was founded on October 22, 1986 and is based in Bedminster, New Jersey.

Recent Quotes

Symbol Price Chg Chg % Market Cap
NPSP 25.88 -0.70 -2.63% 2.656B
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.